Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercialize via the F ...

Core Insights - Texas Attorney General Ken Paxton has filed a lawsuit against Bristol Myers Squibb and Sanofi, alleging that the companies failed to disclose the ineffectiveness of Plavix in preventing blood clots for certain patients [1] Company Summary - Bristol Myers Squibb and Sanofi are being accused of not providing adequate information regarding the efficacy of Plavix, a medication commonly used to prevent blood clots [1]